North American Report

Atopic Dermatitis Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Atopic Dermatitis Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

November 15
19:38 2022
Atopic Dermatitis Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Atopic Dermatitis pipeline constitutes 100+ key companies continuously working towards developing 100+ Atopic Dermatitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Atopic Dermatitis Overview

Eczema, also called atopic dermatitis, is a common allergic skin disease that usually starts in early childhood. It can be associated with infection (bacteria, fungi, yeast and viruses) of the skin. Atopic dermatitis is common worldwide. People of all ages from newborns to adults 65 years of age and older live with this condition. Half of patients with moderate to severe eczema also suffer from asthma, hay fever (allergic rhinitis), and food allergies.

 

Atopic Dermatitis Pipeline Insight, 2022 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atopic Dermatitis Market. 

 

The Atopic Dermatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Atopic Dermatitis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Atopic Dermatitis treatment therapies with a considerable amount of success over the years. Atopic Dermatitis Key players such as – Nektar Therapeutics, Golden Biotechnology Corporation, Ichnos Sciences, Vanda Pharmaceuticals, and others, are developing therapies for the Atopic Dermatitis treatment 
  • Atopic Dermatitis Emerging therapies such as – NKTR-358, Antroquinonol, ISB 830, Tradipitant, Roflumilast, and others are expected to have a significant impact on the Atopic Dermatitis market in the coming years.   
  • In January 2021, Arcutis Biotherapeutics initiated a Phase III trial titled “A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects With Atopic Dermatitis”. 

 

Atopic Dermatitis Pipeline Therapeutics Assessment

  • Atopic Dermatitis Assessment by Product Type
  • Atopic Dermatitis By Stage and Product Type
  • Atopic Dermatitis Assessment by Route of Administration
  • Atopic Dermatitis By Stage and Route of Administration
  • Atopic Dermatitis Assessment by Molecule Type
  • Atopic Dermatitis by Stage and Molecule Type

 

DelveInsight’s Atopic Dermatitis Report covers around 100+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration 

 

Emerging Atopic Dermatitis Drugs Under Different Phases of Clinical Development Include:

  • NKTR-358: Nektar Therapeutics
  • Antroquinonol: Golden Biotechnology Corporation
  • ISB 830: Ichnos Sciences
  • Tradipitant: Vanda Pharmaceuticals
  • Roflumilast: Arcutis Biotherapeutics

 

Get a Free Sample PDF Report to know more about Atopic Dermatitis Pipeline Assessment https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr

 

Atopic Dermatitis Pipeline Analysis:

The Atopic Dermatitis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the Atopic Dermatitis treatment with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Dermatitis Treatment.
  • Atopic Dermatitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Atopic Dermatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atopic Dermatitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Atopic Dermatitis product details are provided in the report. Download the Atopic Dermatitis pipeline report to learn more about the emerging Atopic Dermatitis therapies

 

Atopic Dermatitis Pipeline Market Drivers

  • Rising prevalence of Atopic Dermatitis
  • Escalating expenditure on health care

 

Atopic Dermatitis Pipeline Market Barriers

  • Over-the-counter medications
  • Outdated treatment recommendations
  • Poor prognosis and treatment adherence

 

Scope of Atopic Dermatitis Pipeline Drug Insight    

  • Coverage: Global
  • Key Atopic Dermatitis Companies: Nektar Therapeutics, Golden Biotechnology Corporation, Ichnos Sciences, Vanda Pharmaceuticals, and others
  • Key Atopic Dermatitis Therapies: NKTR-358, Antroquinonol, ISB 830, Tradipitant, Roflumilast, and others
  • Atopic Dermatitis Therapeutic Assessment: Atopic Dermatitis current marketed and Atopic Dermatitis emerging therapies
  • Atopic Dermatitis Market Dynamics:  Atopic Dermatitis market drivers and Atopic Dermatitis market barriers 

 

Request for Sample PDF Report for Atopic Dermatitis Pipeline Assessment and clinical trials 

 

Table of Contents

1

Atopic Dermatitis Report Introduction

2

Atopic Dermatitis Executive Summary

3

Atopic Dermatitis Overview

4

Atopic Dermatitis- Analytical Perspective In-depth Commercial Assessment

5

Atopic Dermatitis Pipeline Therapeutics

6

Atopic Dermatitis Late Stage Products (Phase II/III)

7

Atopic Dermatitis Mid Stage Products (Phase II)

8

Atopic Dermatitis Early Stage Products (Phase I)

9

Atopic Dermatitis Preclinical Stage Products

10

Atopic Dermatitis Therapeutics Assessment

11

Atopic Dermatitis Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Atopic Dermatitis Key Companies

14

Atopic Dermatitis Key Products

15

Atopic Dermatitis Unmet Needs

16 

Atopic Dermatitis Market Drivers and Barriers

17

Atopic Dermatitis Future Perspectives and Conclusion

18

Atopic Dermatitis Analyst Views

19

Appendix

20

About DelveInsight

 

Download Sample PDF Report to know more about Atopic Dermatitis drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/